Cliner

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cliner

What is Cliner? Definition and Classification

Property Description
Active ingredient Clindamycin Phosphate
Form Topical Solution, Gel, Lotion, or Oral Capsule
Pharmacological class Lincosamide Antibiotic
General purpose To inhibit the growth of susceptible bacteria
Origin Semi-synthetic (derived from Lincomycin)

Cliner is the trade name for a medication containing the active ingredient Clindamycin Phosphate, which is formally classified as a lincosamide antibiotic. This type of medication belongs to the broader category of antibacterial agents and is specifically intended to manage infections caused by susceptible anaerobic bacteria and certain Gram-positive cocci. The drug is generally available by prescription-only (Rx) status. Clindamycin has a targeted antibacterial mechanism.

The core substance, Clindamycin, is semi-synthetic, meaning its structure was chemically derived from its natural parent compound, Lincomycin, to enhance its therapeutic properties. This classification indicates that the drug is a targeted therapy used for specific bacterial threats. A common use scenario for the topical formulations of Cliner is in the management of specific skin and skin structure infections where bacterial involvement is confirmed.


Active Ingredient and Available Forms

The crucial component in Cliner is Clindamycin Phosphate, which acts as an inactive prodrug. It must undergo hydrolysis after administration to convert into the therapeutically active agent, Clindamycin, which is the form that actually fights the infection. The use of the phosphate ester as a water-soluble prodrug is a distinguishing formulation feature that improves its stability and allows for versatile delivery.

Cliner is available in multiple common dosage forms, including a topical solution or topical gel for local application, as well as an oral capsule or an injectable solution for systemic needs. The topical solution and topical gel forms are often positioned for use in patients 12 years of age and over. For topical applications, the formulation uses a liquid vehicle base—often containing solvents like isopropyl alcohol or propylene glycol—to aid in delivering the active ingredient efficiently into the skin.


General Purpose and Mechanism Summary

The general purpose of this medication is to interrupt the growth cycle of susceptible bacteria, thereby controlling a bacterial infection. The active drug achieves this effect by causing a protein production blockade. This confirms that the primary role of the medicine is to fight the infection by stopping the organisms from multiplying.

It works by specifically binding to the bacteria's 50S ribosomal subunit, which is the site responsible for assembling the essential proteins that the bacterium needs to survive and replicate. This mechanism is for inhibiting bacterial proliferation. Through the inhibition of bacterial protein synthesis, the drug effectively stops the progression of the infection, making it a valuable agent against targeted bacterial threats.

What side effects are possible with Cliner?

Possible Side Effects and Safety Information

Adverse reactions to Cliner are primarily associated with chemical exposure and potential systemic effects from certain active components. Safety information is based on governmental regulatory assessments from bodies such as the FDA and EMA, which detail risks associated with chemical handling and specific drug classes.

Documented Adverse Reactions

The most commonly documented effects involve the skin, eyes, and respiratory system. These include:

  • Corrosive Injuries: Severe burns or irritation to the skin and eyes, particularly with products containing corrosive chemicals, are documented serious adverse reactions.
  • Respiratory Irritation: Inhalation of mists, vapors, or gases can cause irritation to the nose, throat, and lungs, which may be severe and potentially life-threatening if hazardous chemicals are improperly mixed (e.g., bleach and ammonia).
  • Serious/Long-lasting Effects: Regulatory guidance identifies the risk of disabling, long-lasting, and potentially irreversible adverse reactions (affecting systems such as the nervous system, tendons, and muscles) associated with specific, restricted drug classes (e.g., fluoroquinolones) that may be found in some products.

Safety Restrictions and Precautions

Official documents mandate several safety precautions to mitigate these risks:

Consideration Key Regulatory Instruction
Mixing Chemicals Strictly prohibited due to the risk of creating more hazardous chemical mixtures or dangerous gases.
Handling/Ventilation Use must adhere to label instructions, including required dilution rates and ensuring proper ventilation during and after application.
Vulnerable Populations Products must be stored in areas inaccessible to children. Special caution is advised for elderly patients or those with pre-existing conditions (such as kidney disease) when using related systemic drug classes, due to an increased risk of specific adverse effects like tendon damage.

Should signs of a serious adverse reaction—such as tendon pain/swelling or symptoms of neuropathy—occur with systemic exposure to related drug classes, the regulatory standard requires immediate discontinuation of treatment to help prevent the development of potentially irreversible adverse reactions.

Overdose and Emergency Response

Overdose involving Cliner may manifest with signs such as bloody or watery diarrhea, and greater gastrointestinal side effects are documented with higher systemic exposure. The topical formulation can be absorbed in amounts sufficient to cause systemic effects. Severe and life-threatening outcomes are documented in regulatory sources. These include cardiopulmonary arrest and hypotension following excessively rapid intravenous administration, as well as the reported risk of acute kidney injury. Furthermore, exposure carries the risk of Clostridioides difficile-Associated Diarrhea (CDAD), which can progress to fatal colitis.

Due to the severity of documented outcomes, regulatory guidance mandates that individuals get medical help right away if an overdose is suspected. Urgent medical attention is required when specific life-threatening signs appear: Call emergency services (911) immediately if the individual has collapsed, had a seizure, exhibits trouble breathing, or cannot be awakened. Contacting a Poison Control center is also mandated. Overdose management relies on symptomatic and supportive treatment, as official documents indicate that hemodialysis and peritoneal dialysis are ineffective procedures for drug removal. Elderly patients with severe illness are noted to have a greater risk for adverse reactions related to diarrhea.

Therapeutic Uses of Cliner

What Cliner Treats: Main Uses and Benefits

The medication is commonly used to help with conditions presenting with systemic or localized discomfort.

Cliner is applied across domains where additional symptomatic support is needed in managing conditions marked by increased physiological stress, such as those affecting the abdomen, pelvic region, and lower respiratory tract. It helps address symptoms related to systemic imbalance, including high fever. This support helps maintain a sense of stability when symptoms are more noticeable.

It is relevant for easing the impact of symptoms related to inflammatory or irritative states like cellulitis, dental abscesses, and the pustules and papules of acne vulgaris. The medication provides symptomatic support across these domains, which include serious deep-tissue infections, skin and soft tissue issues, and is considered relevant for patients with a penicillin allergy.

“Its role is often described as providing symptomatic relief that helps patients cope more steadily with difficult episodes of infection.”

Quick Fact: Relief for Inflammatory Symptoms

Quick Fact: Relief for Inflammatory Symptoms Cliner assists with maintaining functional stability during acute episodes by contributing to easing the overall symptom load associated with susceptible bacterial infections.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Cliner

Regulatory agencies define specific patient groups who must not use Cliner (contraindications) and those who require restricted or conditional use.

Contraindicated Populations

Use of Cliner is strictly forbidden for the following groups, as stated in the official regulatory label:

  • Individuals with a confirmed hypersensitivity to the active substance or its excipients.
  • Patients with a history of Crohn’s Disease or Ulcerative Colitis.
  • Individuals with a history of uncontrolled severe unstable angina or Myocardial Infarction within the last six months.

Age and Reproductive Status Exclusions

Population Group Regulatory Status
Children under 6 years Contraindicated (safety/efficacy not established).
Adolescents (6–18 years) Use Established (requires specific dosage).
Pregnancy (1st Trimester) Prohibited (Contraindicated).
Lactation (Breastfeeding) Not Recommended (excretion into breast milk demonstrated).

Condition-Specific Limitations

Eligibility is limited by organ function. Patients with severe renal impairment (Creatinine Clearance <30 mL/min) or moderate-to-severe hepatic impairment may require dose restrictions and intensive monitoring. Patients with certain pre-existing hematologic abnormalities also require restricted use and mandatory regular blood counts, as defined in the product labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents specify several interaction patterns for Cliner (Clindamycin) involving co-administered medicines and specific substances.

Interaction Entity Official Regulatory Outcome/Description
Erythromycin (Macrolide Antibiotic) Co-administration is formally not recommended due to documented in vitro antagonism.
Neuromuscular Blocking Agents (NMBAs) Clindamycin has inherent neuromuscular blocking properties and may enhance the action of these agents.
Vitamin K Antagonists Association with increased coagulation tests (PT/INR) and/or bleeding is officially reported in safety data.

Specific restrictions apply to the injectable form. Clindamycin solution is physically incompatible with several agents when mixed, including Ampicillin sodium and Magnesium sulfate, and must not be co-mixed in solution.

Administration and Pharmacokinetic Constraints

  • Administration of the oral capsule form with food does not appreciably modify the serum concentrations of the active drug.
  • No explicit statement detailing a mandatory dose timing separation rule is documented in the prescribing information for any co-administered substance.
  • The regulatory documents reviewed do not detail formal statements concerning interactions with alcohol or herbal products, nor do they specify explicit CYP-mediated or transporter-based drug interactions.
  • Population-specific interaction severity (e.g., for hepatic or renal impairment) is not explicitly detailed as a formal drug-drug interaction statement in the primary labeling.

Mechanism of Action

The mechanism of action for Clindamycin (the active molecule derived from the Clindamycin Phosphate prodrug) involves disrupting biological processes essential for bacterial growth and replication. Its action operates via a specific molecular interaction that results in the inhibition of bacterial proliferation.


Blocking Protein Production at the 50S Ribosome

The active agent, Clindamycin, acts through binding to the bacteria's internal machinery: the 50S ribosomal subunit . By binding to the 23S rRNA component, Clindamycin operates as a specific inhibitor that physically blocks the ribosome's movement (translocation) along the genetic template. This interaction prevents the formation of peptide bonds, effectively halting the elongation of the bacterial protein chains.


Cessation of Bacterial Proliferation

The immediate consequence of this molecular blockade is the arrest of the bacterial protein synthesis pathway. Since the bacteria cannot manufacture the essential structural components and enzymes necessary for cellular division, their growth and multiplication (proliferation) is severely suppressed. This results in a bacteriostatic effect—meaning it limits the increase in the bacterial population—allowing for the host's defense mechanisms to address the residual bacterial population.

Dosage and Administration Information

Official Administration Guidelines for Cliner

The usage parameters for Cliner (Clindamycin) cover specific routes, dosage schedules, and administration conditions.

Feature Official Use Principle
Route of Administration Systemic use is achieved via oral capsules or solution, or through Intravenous (IV) or Intramuscular (IM) injection. Local use is delivered via topical solutions or gels and vaginal forms.
Standard Dosing Frequency Systemic doses are administered in two, three, or four equal portions per day. Topical forms are generally applied once or twice daily.
Adult Systemic Dose Range Oral doses typically range from 150 mg to 450 mg per administration. Parenteral (IV/IM) doses can range from 600 mg to 2700 mg in total per day, divided as needed.
Course Duration For specific infections, treatment must be continued for a minimum of 10 days.

Administration-Specific Requirements

  • Oral Intake: Oral capsules must be consumed with a full glass of water (6 to 8 ounces) to mitigate the risk of esophageal irritation. The presence of food does not typically affect absorption.
  • Intravenous Protocol: IV infusion rates are restricted and must not exceed 30 mg per minute. The parenteral solution requires dilution prior to administration.
  • Population Adjustments: No standardized dosage modification is required for older adult patients or those with renal or hepatic impairment, provided their function is otherwise stable.
  • Injection Limit: Intramuscular injections are limited to a maximum of 600 mg at any single injection site.

These parameters describe the procedural framework for the medicine, defining the form, timing, and conditions of intake.

Recent Clinical Evidence

Research evidence / Overview of Studies for Cliner

This overview summarizes the official clinical research that has evaluated Cliner (Clindamycin Phosphate), describing the types of studies conducted and what the resulting data have shown so far, according to authoritative sources. This information is intended for context only and does not contain treatment instructions or medical advice.


Evidence for Use in Acne Vulgaris (Topical Formulations)

The evidence base primarily consists of short-term Randomized Controlled Trials (RCTs) and systematic reviews conducted in adolescents and adults with mild to moderate acne. Research examined how symptoms evolved by monitoring outcomes related to inflammatory or irritative states, such as tracking the changes in the count of papules and pustules. Research highlights the tracking of changes measured during the study period, including observed patterns in inflammatory lesion counts. Findings show patterns where changes were measured when Cliner was used as a component of a fixed-dose combination product compared to its use alone. Long-term effects are not fully established, and a persistent research concern is the potential for microbial resistance development with prolonged use.

Evidence for Use in Serious Anaerobic Infections (Systemic Use)

Systemic Cliner was studied for use in conditions associated with acute or disruptive episodes, such as serious infections in the abdomen or pelvis. The evidence includes RCTs that compared Cliner-containing regimens against other antimicrobial therapies. Studies monitored outcomes related to systemic or functional imbalance, such as assessing the rate of clinical response and health maintenance measures over defined time intervals. Research describes its evaluation for susceptible infections in specific patients, such as those with a penicillin allergy. The evidence quality varies across studies due to diverse clinical settings, and research is ongoing to fully understand the impact of emerging antibiotic resistance.

Evidence for Use in Skin and Soft Tissue Infections (SSTI)

Cliner was evaluated in research exploring short-term symptom changes related to conditions marked by inflammatory or irritative states (e.g., cellulitis). Research examined outcomes reflecting daily functioning, focusing on the observed pattern of clinical status and the necessity for further procedures. Studies highlight patterns related to the change in infection signs across the acute treatment phase. Comparative evidence is lacking against other studied treatments across several indications, and long-term outcomes regarding the patterns of infection return are limited.

Key Studies & References

  1. Efficacy and safety of clindamycin phosphate 1.2% and tretinoin 0.025% gel in the treatment of acne vulgaris: a review of the clinical evidence (Systematic Review supporting Acne Evidence)
  2. Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections (Supporting SSTI Evidence)
  3. Antimicrobial Agents: Lincosamides (General Pharmacological Classification and Mechanism Basis)

Frequently Asked Questions (FAQ)

Common questions about Cliner (FAQ)


Q: Is Cliner considered a long-term treatment option?

Cliner is primarily prescribed to treat acute bacterial infections, and official treatment duration is often specific to the infection. Official information indicates that prolonged use is associated with a need for caution because of the potential for developing microbial resistance and serious gut issues, such as C. difficile-associated diarrhea.


Q: How long after starting Cliner might someone expect to see a change?

Regulatory documents describe the effectiveness of Cliner by monitoring clinical status over set time intervals. While official information does not provide a specific timeline for noticing improvement, the active substance is known to be absorbed relatively quickly after administration.


Q: Are the effects of Cliner permanent once the treatment is stopped?

The drug's primary therapeutic effect is to manage an active infection during the treatment course. Regulatory data indicates that the underlying condition may potentially return after the treatment course is completed.


Q: What is the risk of a severe allergic reaction to Cliner?

Official safety information classifies a confirmed hypersensitivity or allergy to Cliner as a strict contraindication (it must not be used). Severe allergic reactions, including serious skin conditions like Stevens-Johnson syndrome and anaphylaxis, have been reported in safety data. In the event of signs of a severe allergic reaction, official guidance mandates immediate discontinuation of the medication.


Q: What are the most commonly reported less serious side effects of Cliner?

The official adverse reaction profiles indicate that the most commonly reported effects involve the stomach and digestive system, such as mild nausea, vomiting, or diarrhea. For topical forms, less serious effects frequently noted include local skin irritation, dryness, or increased oiliness.


Q: Do effectiveness studies on Cliner include diverse patient groups?

The summaries of clinical trials found in regulatory documents describe the study populations where the drug’s effectiveness was evaluated. This information specifies characteristics such as the age range (e.g., adolescents and adults) and gender composition of the groups that participated in the trials.


Q: Is there a particular time of day Cliner is usually taken?

Official administration guidelines detail how often Cliner should be taken but do not require consumption at a specific time of day (e.g., morning or night). The prescribed frequency is generally intended to ensure doses are spaced evenly throughout the day.


Q: Are there specific storage instructions for Cliner based on its formulation?

Yes, storage conditions vary depending on the type of formulation. Both injectable solutions and oral capsules typically require storage at controlled room temperature. Due to its flammable base, the topical solution often carries warnings against storing it near heat, sparks, or open flames.


Q: Does Cliner cause tiredness or affect daily energy levels?

The adverse reaction profiles officially documented for Cliner do not commonly include statements related to tiredness (fatigue) or significant changes to a person’s daily energy levels.


Q: Is Cliner known to interact with common pain relievers?

Regulatory documents provide detailed warnings for interactions with specific drug classes, such as blood thinners and neuromuscular blocking agents. Official information does not specifically list formal interaction statements for common over-the-counter pain relievers.


Q: What happens if a dose of Cliner is missed?

Instructions for a missed dose are typically provided in the patient information leaflet, detailing when to take a forgotten dose versus when to resume the regular schedule. Doubling up on doses is generally advised against in patient guidance.


Q: Is Cliner thought to be habit-forming or addictive?

Cliner (Clindamycin) is officially classified as a prescription-only (Rx) antibacterial agent. Its classification indicates that it has not been identified as a substance with significant potential for abuse or dependency.


Q: How long does Cliner stay in the system after the last dose?

Regulatory data provides the half-life of the active substance, which helps determine the duration of its presence in the body. Cliner is primarily eliminated from the body via excretion in urine and feces, meaning the active substance is eliminated over time.


Q: Is it normal to feel a change in appetite while on Cliner?

Official adverse reaction lists include documented gastrointestinal effects that can affect appetite. These may include anorexia (loss of appetite) or dysgeusia (taste disturbance).


Q: Does Cliner interact with hormonal birth control?

Official regulatory warnings do not typically include formal interaction statements specifically related to hormonal birth control. Individuals with concerns about birth control effectiveness may wish to consult with a healthcare professional.


Q: Can Cliner affect a person's ability to drive or operate machinery?

The official product information for Cliner generally states that no effects on the ability to drive or use heavy machinery are known or documented in clinical studies.


Q: Is Cliner available as a generic medicine?

Cliner is the trade name for the active ingredient Clindamycin Phosphate. This drug is widely available from multiple manufacturers under its generic name, Clindamycin.


Q: Does taking Cliner affect the way other medicines are absorbed?

The active substance in Cliner is processed by specific liver enzymes and is known to function as a weak inhibitor of the CYP3A4 enzyme. This process means Cliner may potentially influence the concentration or duration of other co-administered medicines.


Q: Is Cliner a newer drug, or has it been around for a while?

Clindamycin, the active substance, is derived from the older antibiotic Lincomycin and is considered a semi-synthetic drug. It has been available for clinical use for several decades, having received initial regulatory approval in the early 1970s.


Q: Can Cliner cause changes in mood or emotional state?

Adverse reaction data lists certain systemic effects that have included reports of minor emotional and mood changes. These are generally categorized as a psychiatric disorder, but they are typically not listed as common or frequent side effects.


Q: What is the official information regarding weight changes while on Cliner?

The adverse reaction data officially documented for Cliner does not typically include weight changes (either gain or loss) among the commonly reported side effects observed in clinical trials.


Q: Can Cliner be split or crushed (as a clarification question about the formulation)?

Official instructions advise that oral capsules should be swallowed whole with a full glass of water. The formulation is designed to be swallowed whole; altering the capsule is typically discouraged in patient guidance.


Q: What official warnings are there about stopping Cliner suddenly?

Official guidance advises patients to always complete the full course of treatment as prescribed, even if symptoms improve. This is typically recommended to support the full resolution of the infection and help discourage the development of drug-resistant bacteria.


Q: Does Cliner have any known effects on heart rate or blood pressure?

Serious adverse reaction reports for the injectable form of Cliner include documented effects on the heart and circulation. These include low blood pressure (hypotension) and cardiopulmonary arrest, which may occur if the intravenous infusion rate exceeds the recommended speed.


Q: Are there studies comparing the patient experience on Cliner versus placebo?

Effectiveness studies cited in regulatory documents for topical Cliner formulations have included comparisons against a vehicle (or placebo) control, particularly in the management of acne vulgaris.


Q: Does Cliner have a risk of drug-induced liver injury (as an informational query)?

Regulatory documents include reports of changes in liver function tests (elevated enzyme levels) and, on rare occasion, jaundice or liver injury. Caution is noted in regulatory documents, especially for patients who have pre-existing hepatic (liver) impairment.


Q: Is Cliner a controlled substance?

Cliner (Clindamycin) is officially classified as a prescription-only (Rx) antibacterial agent and is not designated as a controlled substance by regulatory authorities.


Q: Can people with diabetes use Cliner?

Official warnings and contraindications do not list diabetes as a specific restricting factor for the use of Cliner. However, as with any medication, healthcare professionals typically advise close monitoring of overall health status and any pre-existing conditions during treatment.


How should Cliner be stored and disposed of?

How to Store and Dispose of Cliner

Cliner (clindamycin phosphate topical solution) must be stored according to official regulatory requirements to maintain its stability.


Storage Requirements

Cliner must be stored at Controlled Room Temperature, defined as between 20 C and 25 C (68 F and 77 F). Storage conditions prohibit freezing and require protection from heat, spark, and flames due to the product's flammability. The medication must be kept in its original container with the bottle tightly closed and stored out of the reach of children.


Disposal Instructions

Unused or expired Cliner should be disposed of following your pharmacist's recommendations or the instructions of the local waste disposal company. Do not dispose of this medication by flushing it down a toilet or pouring it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cliner found in:

A-Z Index: